Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kodiak Sciences Inc.

NASDAQ: KOD · Life Sciences · 8 alerts · CIK 1468748

Share price
$100.73Close, Nov 16
Market cap
$6.59B
Shares outstanding
65.4MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kodiak Sciences Inc. filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results

Kodiak Sciences Q3 2026 Results: Net Loss of $66.2M, Loss Widens

Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.

Key figure
Net loss $66.2M
4:00 PM ET 8-K
Financial Results

Kodiak Sciences Financial Results

Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.

“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
4:55 PM ET Form 4
Insider Buying

Kodiak Sciences Director Baker Bros. Advisors LP Buys $24.3M of Stock

Baker Bros. Advisors LP, Director, bought 247,090 shares of Kodiak Sciences Inc. at $98.51 a share, worth $24.3M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 20,424,859 (+0.4%).

Value
$24.3M
Shares
247,090
Average price
$98.51
Role
Director
Holding change
+0.4%
Trade date
Nov 4, 2026 to Nov 5, 2026
5:00 PM ET Form 4
Insider Selling

Kodiak Sciences CFO John A. Borgeson Sells $2.69M of Stock

John A. Borgeson, CFO, sold 29,900 shares of Kodiak Sciences Inc. at $87.67 to $93.71 a share (average $89.99) in 7 transactions, worth $2.69M in total on Oct 21, 2026. Shares held after the trade: 212,030 (-0.9%).

Value
$2.69M
Shares
29,900
Average price
$89.99
Role
CFO
Holding change
-0.9%
Trade date
Oct 21, 2026
4:31 PM ET Form 4
Insider Buying

Kodiak Sciences Director Baker Bros. Advisors LP Buys $63.4M of Stock

Baker Bros. Advisors LP, Director, bought 715,508 shares of Kodiak Sciences Inc. at $84.24 to $89.86 a share (average $88.59) in 21 transactions, worth $63.4M in total between Sep 28, 2026 and Sep 29, 2026. Shares held after the trade: 19,772,333 (+0.5%).

Value
$63.4M
Shares
715,508
Average price
$88.59
Role
Director
Holding change
+0.5%
Trade date
Sep 28, 2026 to Sep 29, 2026
4:30 PM ET Form 4
Insider Buying

Kodiak Sciences Director Baker Bros. Advisors LP Buys $34.9M of Stock

Baker Bros. Advisors LP, Director, bought 418,105 shares of Kodiak Sciences Inc. at $79.40 to $85.97 a share (average $83.58) in 26 transactions, worth $34.9M in total on Sep 28, 2026. Shares held after the trade: 19,153,010 (+0.0%).

Value
$34.9M
Shares
418,105
Average price
$83.58
Role
Director
Holding change
+0.0%
Trade date
Sep 28, 2026
4:29 PM ET Form 4
Insider Buying

Kodiak Sciences Director Baker Bros. Advisors LP Buys $58.6M of Stock

Baker Bros. Advisors LP, Director, bought 807,840 shares of Kodiak Sciences Inc. at $61.21 to $78.57 a share (average $72.57) in 30 transactions, worth $58.6M in total on Sep 28, 2026. Shares held after the trade: 18,435,276 (+0.0%).

Value
$58.6M
Shares
807,840
Average price
$72.57
Role
Director
Holding change
+0.0%
Trade date
Sep 28, 2026
8:54 AM ET 8-K
Clinical Trial Data

Kodiak Sciences Clinical Trial Data

Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.